Looker Benjamin sold (to issuer) 667,524 shares of ESPR
Looker Benjamin (Chief Legal Officer) sold (to issuer) 667,524 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
The newest fact is the reported sale of 667,524 shares by the Chief Legal Officer to the issuer, leaving 0 shares after the transaction.
Market read
Traders may note insider selling activity, but the filing provides no price, no stated rationale, and no accompanying operational or financial update.
What to watch
No 10b5-1 plan is indicated, but the transaction is to the issuer and the price is not disclosed, reducing interpretability versus open-market sales with known pricing.
Background
The article is a SEC Form 4 insider transaction for Esperion Therapeutics, filed 2026-07-13.
Ticker impact
Esperion Therapeutics disclosed a Form 4 showing Chief Legal Officer Looker Benjamin sold 667,524 shares to the issuer on 2026-07-13.
Likely limited near-term impact; treat as routine insider liquidity unless corroborated by other disclosures.
The filing is primary-source (Form 4) but lacks price/value and provides no stated reason or follow-on corporate event; insider sales are often non-informational, especially when price is undisclosed and holdings drop to zero.
Market effects
No clear sector read-through from a single insider sale without additional company-specific catalysts.
None indicated.
None indicated.
Counterpoint
The sale could be part of a planned liquidity event or issuer buyback mechanics, so it may not reflect negative expectations.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderLooker Benjamin
Chief Legal Officer who sold 667,524 shares to the issuer.